Ultralife Q1 sales up 31.4% to $41.9M; GAAP EPS $0.18 vs -$0.02 YoY

ULTRALIFE CORP

2024-Q1 EPS reported $0.21 revenue$41,927,000

Revenue $41.9M (+31.4% YoY); government/defense sales +83.4%, medical battery sales +54.7%.
GAAP EPS $0.18 vs net loss $0.02; adjusted EPS $0.21. Operating income $4.1M vs breakeven.
Gross margin 27.4% vs 23.3% YoY; Battery & Energy margin 25.7% vs 22.9%.
Backlog $97.4M; adjusted EBITDA $5.2M (12.5% of sales) vs $1.2M (3.6%).
CEO cites gross margin initiatives and core product demand; expects profitable growth and cash flow.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ULTRALIFE CORP reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On April 25, 2024, Ultralife Corporation issued a press release regarding the financial results for its first quarter ended March 31, 2024.

View on SEC.gov

411 earnings releases filed in the last 30 days. Browse all earnings releases →

ULTRALIFE CORP filing history →

Source: SEC EDGAR

accession 0001437749-24-013119

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.